Eiger Group International, Inc.

Palo Alto, CA 94301

SBIR Award Summary

Total Number of Awards 5
Total Value of Awards $3.57MM
First Award Date 05/01/10
Most Recent Award Date 09/01/16

Key Personnel

Last Name Name Awards Contact
Glenn Jeffrey S Glenn 1
Murphy Brian S Murphy 3
GROSS COLEMAN GROSS 1

5 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 09/01/16 - 09/30/17

? DESCRIPTION (provided by applicant): Our goal is to develop a low cost therapy for hepatocellular carcinoma (HCC), an important worldwide cause of cancer-related death with over 500,000 cases diagnosed each year. 5-year survival rates are less than 12%, and there is an urgent need for effective therapies. Risk factors include chronic hepat...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-10-124
Budget: 05/01/13 - 04/30/14

DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) is an important worldwide cause of liver disease. Current standard of care (SOC) agents are inadequate for most patients, and new virus-specific drugs are urgently needed. Our long-term objective is to bring a new class of anti-HCV drugs to the clinic. We discovered that the HCV NS4B p...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-10-124
Budget: 05/01/12 - 04/30/13

DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) is an important worldwide cause of liver disease. Current standard of care (SOC) agents are inadequate for most patients, and new virus-specific drugs are urgently needed. Our long-term objective is to bring a new class of anti-HCV drugs to the clinic. We discovered that the HCV NS4B p...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-10-124
Budget: 05/15/11 - 04/30/12

DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) is an important worldwide cause of liver disease. Current standard of care (SOC) agents are inadequate for most patients, and new virus-specific drugs are urgently needed. Our long-term objective is to bring a new class of anti-HCV drugs to the clinic. We discovered that the HCV NS4B p...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-09-116
Budget: 05/01/10 - 04/30/11

DESCRIPTION (provided by applicant): Over 150 million people worldwide are infected with the hepatitis C virus (HCV), which is an important cause of chronic liver disease. Current therapies are inadequate. Our long-term objective is to bring a new class of anti-HCV drugs to the clinic. We recently discovered and genetically validated a new targe...